print version 

Find company
Home About the ProjectContact usFor the Clients
Enter code or ISIN
 
alpha / industry search

Issuers' Corner
Press Releases
Annual Reports Library

Financial Statements
SEC & FFMS Filings
Corporate Presentations
GM Materials
Issues Documents
Corporate Governance Materials
Russian Company Guide
Company Profiles
Corporate Calendar
Markets Corner
Consensus Estimates
Media Corner
News Line


Get updates



Home  Issuers' Corner  Press Releases  Financial Corporation "Sistema" REGISTER LOG IN

Press Releases > Financial Corporation "Sistema"  all about the company

company search
all press releases
all Financial Corporation "Sistema" press releases

Financial Corporation "Sistema"

February 19, 2021

Sistema and RDIF agree to jointly develop Binnopharm Group

Sistema PJSFC (Sistema, the Corporation or, together with its subsidiaries and affiliates, the Group) (LSE: SSA, MOEX: AFKS), a publicly-traded Russian investment company, announces completion of the establishment of the pharmaceutical holding company Binnopharm Group (“Binnopharm Group” or  Holding).

To create the pharmaceutical holding company, Sistema and its financial partner, VTB Group (VTB), contributed their 56.2% stake in OJSC Sintez (which includes CJSC Biocom) to the equity of Binnopharm Group. At the same time, Sistema, VTB and a consortium of investors consisting of the Russia-China Investment Fund (a fund established by the Russian Direct Investment Fund and China Investment Corporation) and major Middle East funds (collectively, the Investor Consortium) contributed an 85.6% stake in JSC Alium (which includes JSC Binnopharm) to the equity of Binnopharm Group. As a result, the effective stake of Sistema together with VTB in Binnopharm Group will be 79%, and the Investor Consortium will have 15.8%. The remaining 5.2% of shares are distributed among individual minority shareholders.

Consolidation of pharmaceutical assets on the basis of Binnopharm Group is an important step towards transforming the holding into a leader on the Russian pharmaceutical market, with a diversified product portfolio, experienced management, and significant production and research potential. Binnopharm Group companies are already demonstrating impressive performance: in 2020, sales grew by 25% year-on-year to RUB 27.5 bn. Consolidation of assets into a single holding company will support further growth of the business and add shareholder value, including by achieving synergies from the merger, optimisation of marketing and promotion costs, reduction in administrative costs, and expansion of the geographic coverage of sales. We are pleased that our strategy for the development of the pharmaceutical business met with the approval of our partners and they supported the establishment of a single pharmaceutical holding company,” said Vladimir Chirakhov, President of Sistema.

The creation of one of the leading diversified pharmaceutical holdings will allow the development and production of high quality and innovative medicines to increase the wellbeing and life expectancy of the Russian population. One example of such an approach was the start of production of the Sputnik V vaccine against the coronavirus infection at the Binnopharm plant in Zelenograd. The participation of RDIF foreign partners in the consolidation project confirmed their interest in investing in the Russian pharmaceutical and healthcare sectors, their readiness to work together with RDIF on the implementation of national projects, as well as on the further development of the Binnopharm group, including its initial public offering in the future, said Kirill Dmitriev, CEO of the Russian Direct Investment Fund.

Binnopharm Group is a full-cycle Russian pharmaceutical holding company that combines five production sites located in different regions of Russia: JSC Alium (formerly OBL Pharm in the Serpukhov district of the Moscow region), JSC Binnopharm (two sites: Zelenograd and Krasnogorsk), JSC Sintez (Kurgan) and JSC Biocom (Stavropol). Binnopharm Group companies produce a wide range of drugs across various therapeutic areas and collectively have the largest portfolio of drugs among Russian manufacturers (more than 450 registered products, including the COVID-19 vaccine Sputnik V). Binnopharm Group's Chief Executive Officer is Rustem Muratov.


*** 

For further information, please visit www.sistema.com or contact: 

Investor Relations

Evgeniy Chuikov

Tel: +7 (495) 692 11 00

ir@sistema.ru

Public Relations

Sergey Kopytov

Tel.: +7 (495) 228 15 27

kopytov@sistema.ru

 

 

 

 

Search by industry

Agriculture, Foresty and Fishing | Chemicals | Engineering | Ferrous Metals | Financial, Insurance & Real Estate | Food & Kindred Products | General Construction | Information Technology | Media & Publishing | Non-Ferrous Metals | Oil & Gas | Pharmaceuticals | Power Industry | Precious Metals and Diamonds | Telecommunications | Transportation | Wholesale & Retail Trade

Search by alpha index

A B C D F G I K L M N O P R S T U V W X Z


Site Map
© RUSTOCKS.com
Privacy Statement | Disclaimer